Atlas Trials

Alkahest, Inc.

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Alkahest, Inc.

RecordFirmDate
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) (NCT05038020)Alkahest, Inc.2021-08-17
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment (NCT04527328)Alkahest, Inc.2020-04-28
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid (NCT04499235)Alkahest, Inc.2020-01-30
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD (NCT04331730)Alkahest, Inc.2020-01-28
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment (NCT04369430)Alkahest, Inc.2020-01-16
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty (NCT03981419)Alkahest, Inc.2019-07-12
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease (NCT03765762)Alkahest, Inc.2019-01-15
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment (NCT03713957)Alkahest, Inc.2018-11-12
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (NCT03558074)Alkahest, Inc.2018-04-20
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease (NCT03520998)Alkahest, Inc.2018-04-16
Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration (NCT03558061)Alkahest, Inc.2018-04-04

Track Alkahest, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.